Eledon Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ELDN) $1.14 -0.01 (-0.87%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$1.12▼$1.1650-Day Range$1.12▼$1.6952-Week Range$1.07▼$3.70Volume38,488 shsAverage Volume58,054 shsMarket Capitalization$27.59 millionP/E RatioN/ADividend YieldN/APrice Target$10.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Eledon Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside835.7% Upside$10.67 Price TargetShort InterestHealthy0.27% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.89Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.89) to ($1.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector377th out of 957 stocksPharmaceutical Preparations Industry165th out of 444 stocks 3.5 Analyst's Opinion Consensus RatingEledon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.67, Eledon Pharmaceuticals has a forecasted upside of 835.7% from its current price of $1.14.Amount of Analyst CoverageEledon Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.27% of the outstanding shares of Eledon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEledon Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eledon Pharmaceuticals has recently increased by 25.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEledon Pharmaceuticals does not currently pay a dividend.Dividend GrowthEledon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELDN. Previous Next 3.3 News and Social Media Coverage News SentimentEledon Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eledon Pharmaceuticals this week, compared to 1 article on an average week.Search Interest4 people have searched for ELDN on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.40% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 39.40% of the stock of Eledon Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Eledon Pharmaceuticals are expected to grow in the coming year, from ($1.89) to ($1.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eledon Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eledon Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEledon Pharmaceuticals has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Read More ELDN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELDN Stock News HeadlinesNovember 29, 2023 | finance.yahoo.comEledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity ConferenceNovember 10, 2023 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsDecember 3, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 9, 2023 | msn.comEledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?November 9, 2023 | finance.yahoo.comEledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsNovember 8, 2023 | finance.yahoo.comEledon Pharmaceuticals to Present at Jefferies London Healthcare ConferenceNovember 6, 2023 | markets.businessinsider.comPromising Results and Buy Rating for Eledon Pharmaceuticals: Tegoprubart’s Potential in Kidney Transplant TherapyNovember 4, 2023 | markets.businessinsider.comPromising Phase Ib Study Results Bolster Buy Rating for Eledon Pharmaceuticals: An Analysis by Rami KatkhudaDecember 3, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 2, 2023 | finance.yahoo.comEledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationOctober 24, 2023 | msn.comHC Wainwright & Co. Maintains Eledon Pharmaceuticals (ELDN) Buy RecommendationOctober 23, 2023 | msn.comEledon Pharmaceuticals appoints Eliezer Katz as CMOOctober 23, 2023 | markets.businessinsider.comEledon Pharmaceuticals Appoints Eliezer Katz As Chief Medical OfficerOctober 23, 2023 | finance.yahoo.comEledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical OfficerOctober 13, 2023 | finance.yahoo.comEledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual MeetingOctober 2, 2023 | finance.yahoo.comEledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of DirectorsSeptember 28, 2023 | nasdaq.comNoble Capital Markets Initiates Coverage of Eledon Pharmaceuticals (ELDN) with Outperform RecommendationSeptember 27, 2023 | markets.businessinsider.comPromising Clinical Trials and Future Projections Bolster Buy Rating for Eledon PharmaceuticalsSeptember 25, 2023 | finance.yahoo.comEledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a HumanSeptember 20, 2023 | finance.yahoo.comEledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 6, 2023 | finance.yahoo.comEledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman PrimatesSeptember 5, 2023 | finance.yahoo.comEledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney TransplantationAugust 22, 2023 | msn.comCantor Fitzgerald Reiterates Eledon Pharmaceuticals (ELDN) Overweight RecommendationAugust 16, 2023 | finance.yahoo.comEledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney TransplantationAugust 10, 2023 | finance.yahoo.comEledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial ResultsJuly 17, 2023 | finance.yahoo.comIs Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?July 12, 2023 | finance.yahoo.comAmerigo Reports Q2-2023 Production Results and Provides MVC Operational UpdateSee More Headlines Receive ELDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ELDN CUSIPN/A CIK1404281 Webnovustherapeutics.com Phone(949) 238-8090FaxN/AEmployees17Year FoundedN/APrice Target and Rating Average Stock Price Target$10.67 High Stock Price Target$13.00 Low Stock Price Target$9.00 Potential Upside/Downside+835.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.18% Return on Assets-42.79% Debt Debt-to-Equity RatioN/A Current Ratio21.73 Quick Ratio21.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.70 per share Price / Cash Flow1.62 Book Value$3.77 per share Price / Book0.30Miscellaneous Outstanding Shares24,200,000Free Float19,504,000Market Cap$27.59 million OptionableNot Optionable Beta1.64 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. David-Alexandre C. Gros M.D. (Age 51)Ph.D., CEO & Non Independent Director Comp: $807.96kDr. Steven N. Perrin Ph.D. (Age 57)President, Chief Scientific Officer & Non Independent Director Comp: $603.9kMr. Paul Sean Little (Age 58)CFO & Principal Accounting Officer Comp: $611.71kMr. John HerbergerVice President of Technical OperationsMr. Bryan E. Smith J.D. (Age 43)General Counsel, Corporate Secretary & Chief Compliance Officer Comp: $377.14kDr. David Hovland Ph.D.Chief Regulatory OfficerDr. Eliezer Katz F.A.C.S.FACS, M.D., Chief Medical OfficerMore ExecutivesKey CompetitorsNRx PharmaceuticalsNASDAQ:NRXPIterum TherapeuticsNASDAQ:ITRMUnity BiotechnologyNASDAQ:UBXSio Gene TherapiesNASDAQ:SIOXGain TherapeuticsNASDAQ:GANXView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 18,803 shares on 11/15/2023Ownership: 7.538%Jmac Enterprises LLCSold 22,000 shares on 10/19/2023Ownership: 0.246%View All Institutional Transactions ELDN Stock Analysis - Frequently Asked Questions Should I buy or sell Eledon Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eledon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ELDN shares. View ELDN analyst ratings or view top-rated stocks. What is Eledon Pharmaceuticals' stock price target for 2024? 3 brokerages have issued 12-month price targets for Eledon Pharmaceuticals' shares. Their ELDN share price targets range from $9.00 to $13.00. On average, they anticipate the company's share price to reach $10.67 in the next year. This suggests a possible upside of 835.7% from the stock's current price. View analysts price targets for ELDN or view top-rated stocks among Wall Street analysts. How have ELDN shares performed in 2023? Eledon Pharmaceuticals' stock was trading at $2.28 at the start of the year. Since then, ELDN stock has decreased by 50.0% and is now trading at $1.14. View the best growth stocks for 2023 here. Are investors shorting Eledon Pharmaceuticals? Eledon Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 65,900 shares, an increase of 25.8% from the October 31st total of 52,400 shares. Based on an average trading volume of 88,800 shares, the days-to-cover ratio is currently 0.7 days. View Eledon Pharmaceuticals' Short Interest. When is Eledon Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our ELDN earnings forecast. How were Eledon Pharmaceuticals' earnings last quarter? Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) released its earnings results on Thursday, November, 9th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.06. Who are Eledon Pharmaceuticals' major shareholders? Eledon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (7.54%), Jmac Enterprises LLC (0.25%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David-Alexandre C Gros, David-Alexandre C Gros and Paul Sean Little. View institutional ownership trends. How do I buy shares of Eledon Pharmaceuticals? Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ELDN) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.